Teclison

Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.

A platform designed to remodel the tumor immune microenvironment by inducing controlled tumor hypoxia. This triggers tumor necrosis and the release of antigens, which primes a systemic anticancer immune response, particularly to enhance the efficacy of immune checkpoint inhibitors.

Teclison competes in the crowded immuno-oncology combination therapy arena, facing numerous companies developing next-gen cytokines, cancer vaccines, oncolytic viruses, and other TME modulators. Its differentiation lies in its specific hypoxia-inducing mechanism to prime immunity, but it must demonstrate superior clinical efficacy to established and emerging combination regimens.